Introduction {#s1}
============

Replication stress in dividing cells often leads to increased stalled forks and under-replication of the DNA, which can ultimately contribute to elevated DNA damage, mutagenesis and genomic instability ([@bib65]). One of the most common human diseases associated with replication stress is cancer ([@bib4]). The Fanconi Anemia (FA) disease is a chromosomal instability disorder that is caused by biallelic mutations in any of the 21 FA genes; FA is characterized by multiple developmental abnormalities, progressive bone marrow failure and cancer predisposition ([@bib42]; [@bib12]). The FA pathway, which includes FA gene products representing ubiquitin signaling, homology-directed recombination (HDR) and nucleolytic pathways, plays a central role in the repair of DNA interstrand crosslinks (ICLs) and regulates cellular responses to replication stress ([@bib29]; [@bib38]). The FA pathway is activated via lysine site-specific monoubiquitination of two of its effector FA proteins, FANCD2 and FANCI ([@bib17]; [@bib52]; [@bib54]). The molecular details as to how the FA pathway protects against replication failures and how this is related to human disease is still poorly understood. Understanding this fundamental process could represent an attractive therapeutic target against cancers.

The FA pathway is strongly activated by hydroxyurea (HU) ([@bib57]), an inhibitor of ribonucleotide reductase (RNR), which unlike ICL-inducing agents (such as mitomycin C or cisplatin), does not directly elicit DNA lesions that require removal, but induces severe replication fork slowing or stalling through the depletion of the cellular deoxynucleotide pool (dNTPs). Additionally, recent studies found both FANCD2 and FANCI to be associated with the replisome in response to replication fork arrest and that the activation of the FA pathway is critical for protecting stalled forks from nucleolytic degradation of nascent DNA during HU treatment, and for promoting fork restart after HU is removed ([@bib33]; [@bib49]; [@bib13]). How the FA pathway controls fork restart is not well-understood.

The role of translesion DNA polymerases (TLS Pols) as it pertains to the mammalian replication stress response has remained enigmatic. Stalled replication forks that are stabilized by the ATR pathway can be restarted by these error-prone TLS Pols when the source of the stress itself (including bulky DNA adducts or UV crosslinks) cannot be removed in a timely fashion, as in the case of an unrepaired DNA lesion ([@bib65]). Specifically, the replication machinery can 'bypass' these physical barriers at stalled forks by swapping the replicative Pols for TLS Pols; this is known as the DNA damage tolerance (DDT) pathway that is typically initiated by proliferating cell nuclear antigen (PCNA) monoubiquitination and engagement of a specific Y-family TLS Pol (such as Pol eta, kappa, iota, or Rev1) that possess ubiquitin-binding domains (UBDs) ([@bib26]; [@bib9]). The DDT pathway enables the recruitment of TLS Pols to bypass, or 'tolerate', the DNA lesions during or post S-phase DNA synthesis (in the absence of repair) in order to complete genome duplication in a timely manner and promote cell survival, but at a cost of increased mutagenesis ([@bib47]). Here, we set out to identify factors that regulate fork restart under conditions of nucleotide deprivation. Surprisingly, we found that the TLS Pol kappa (PolK) plays a critical role in fork restart during high-dose HU (2 mM) treatment. Importantly, both the FA pathway and PCNA polyubiquitination are critical regulators of PolK recruitment and function at stalled forks. These findings reveal a previously unappreciated role for a Y-family TLS Pol in promoting replication fork recovery during conditions of nucleotide deprivation.

Results {#s2}
=======

TLS polymerase kappa (PolK) is required for efficient replication fork restart {#s2-1}
------------------------------------------------------------------------------

To understand the molecular basis of individual DNA synthesis events under replication stress conditions, we employed the single-molecule DNA fiber technique to study the role of TLS Pols in modulating efficient fork restart from HU-induced stalled replication forks ([Figure 1A](#fig1){ref-type="fig"}). Asynchronous-growing RPE-1 or other human cell lines were initially pulse-labeled with iododeoxyuridine (IdU) to mark all elongating replication forks, followed by a wash step and a high-dose HU (2 mM) treatment to cause dramatic slowing or stalling of all replication forks. The HU was then subsequently washed out and replenished with fresh media to initiate replication fork restart in the presence of chlorodeoxyuridine (CldU) (see DNA fiber labeling schematics, [Figure 1A](#fig1){ref-type="fig"}). The efficiency of fork restart events was quantified by scoring the number of stalled forks (green-only tracks) as compared to restarted forks (green tracks that are immediately followed by red tracks) and calculated as a percentage of stalled forks from the total fork events. Unexpectedly, only PolK, but not Polζ, or other members of the Y-family TLS Pols, is required to promote efficient fork restart after HU treatment, as shown by the increased percentage of stalled forks ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Based on previous work by Helleday and colleagues ([@bib43]), fork restart efficiency as measured by DNA fiber analysis could be highly dependent on the duration of fork-stalling events (time of HU treatment). This appears to be the case as the ability of PolK to rescue stalled forks is linked to a shorter duration of HU treatment (within 4 hr) ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). In contrast, if replication forks are stalled for too long (8 hr or greater), the number of stalled forks increases dramatically even in control cells and they become less dependent on a PolK for fork restart. Under this scenario, stalled forks are more likely to be rescued by dormant origin firing ([@bib18]) (data not shown) or by HDR-related factors ([@bib43]).

![PolK is required for replication fork restart due to nucleotide deprivation.\
(**A**) Schematic for measuring replication fork restart by DNA fiber analysis. Quantification of fork restart efficiency (% stalled forks) in HU-treated (2 mM) RPE-1 cells using two independent siRNAs against individual TLS Pols as indicated. Representative images of the DNA fiber tracts are shown. (**B**) Quantification of fork restart efficiency in RPE-1 cells comparing different HU (2 mM) treatment time-points in the presence or absence of PolK siRNA knockdown. (**C**) Quantification of fork restart efficiency in HU-treated RPE-1 cells with either a wash step with fresh media or with no wash (HU still present) supplemented with 250 μM deoxynucleosides (dNs) for recovery. (**D**) Western blot analysis of RPE-1 cells treated with 2 mM HU for 4 hr followed by either a wash step with fresh media or no wash (HU still present) supplemented with 250 μM deoxynucleosides (dNs) or 250 μM ribonucleosides (rNs) for 30 or 60 min chase. (**E**) Quantification of fork restart efficiency comparing fork-stalling agents, HU (2 mM) or APH (5 μM), in the presence or absence of PolK siRNA knockdown. (**F**) Western blot analysis of RPE-1 cells treated with either HU (2 mM), APH (5 μM), or Gemcitabine (Gem, 1 μM) for 4 hr, followed by a wash step and recovery in fresh media for 2 hr. Data for % stalled forks are represented by mean ± s.d. of three independent experiments and p-values calculated using t-test with Welch's correction. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.](elife-41426-fig1){#fig1}

Next, we wanted to determine whether the PolK-mediated fork restart is specific for rescuing stalled forks caused by nucleotide deprivation. To rule out other potential HU-mediated fork-stalling effects, such as through oxidative stress ([@bib24]), we asked whether supplementing the media with deoxynucleosides (dNs) ([@bib1]) in the presence of HU (no wash step) could rescue HU-mediated stalled forks as measured by CldU labeling of restarted forks (see schematics, [Figure 1C](#fig1){ref-type="fig"}). We found that the percentage of stalled forks were very similar when comparing samples with normal fork restart after HU wash off *versus* samples with added dNs under continuous HU treatment ([Figure 1C](#fig1){ref-type="fig"}). This suggests that replenishing the depleted dNTP pool caused by the high-dose HU treatment for 4 hr with dNs in the media can rescue stalled forks back to the same level as washing out HU. As expected, depletion of PolK elevated stalled forks levels in samples with or without HU wash off supplemented with dNs ([Figure 1C](#fig1){ref-type="fig"}). The rescue of stalled forks in the presence of high-dose HU correlated with checkpoint recovery (decrease in phosphorylated Ser345 Chk1 and Ser33 RPA32 signals) after supplementing with dNs, but not with ribonucleosides (rNs) ([Figure 1D](#fig1){ref-type="fig"}). This is consistent with the fact that HU primarily acts as a potent inhibitor of RNR, which prevents the conversion of ribonucleotides to deoxyribonucleotides, leading to nucleotide deprivation and fork stalling. Thus, supplementing with rNs in HU-treated cells will not replenish the dNTP pool and the forks will remain stalled under HU, leading to prolonged checkpoint activation.

Next, we compared whether other fork-stalling agents, such as aphidicolin (APH) or Gemcitabine (Gem), can behave similarly to HU treatment for fork restart after wash off using the same fork restart DNA fiber assay (see schematics, [Figure 1E](#fig1){ref-type="fig"}). APH is a reversible, potent and specific inhibitor of B-family DNA polymerases ([@bib61]), which includes Polα and the replicative DNA polymerasesδ and ε. Interestingly, in control samples, APH treatment followed by a wash off resulted in higher levels of fork-stalling in comparison to HU treatment, and the depletion of PolK did not further increase fork-stalling events ([Figure 1E](#fig1){ref-type="fig"}). We speculate that the stalled fork structures in HU- *versus* APH-treated cells are likely processed differently ([@bib61]; [@bib2]) due to the fact that unlike HU, APH treatment does not lead to RPA phosphorylation even though both can activate Chk1 ([Figure 1F](#fig1){ref-type="fig"}). Gem, on the other hand, acts as a nucleoside analog that blocks DNA synthesis ([@bib40]). Under our conditions, we failed to detect fork restart and checkpoint recovery after washing off Gem at various doses, thus precluding any analysis of fork restart ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}).

The FA pathway is required for PolK-mediated fork restart {#s2-2}
---------------------------------------------------------

To determine whether PolK functions in the same pathway or in parallel with the FA pathway for fork restart, we used siRNA knockdown strategies in combination with FA patient-derived cells or CRISPR-Cas9-mediated disruption of *PolK* alleles in 293 T cells (sgPolK) to assess the functional link between PolK and the FA pathway. In an extension of our previous findings ([@bib13]), FA fibroblasts from FANCD2-deficient patient cells (PD20) showed defective fork restart that could be corrected by FANCD2 WT complementation, but not its monoubiquitination-defective mutant K561R ([@bib17]) ([Figure 2A](#fig2){ref-type="fig"}). However, the additional knockdown of PolK in PD20 vector control or K561R mutant-expressing cells did not further increase the level of stalled forks, suggesting that PolK is likely epistatic to the FA pathway to facilitate fork restart ([Figure 2A](#fig2){ref-type="fig"}). A Chk1 inhibitor (Chk1i) treatment was utilized as a positive control for replication stress to establish the upper limits of detectable stalled forks in our assay ([Figure 2A](#fig2){ref-type="fig"}). Importantly, the analysis of one of the 293T *PolK* CRISPR clones (sgPolK \#1) demonstrated that GFP-tagged PolK wild-type (WT) expression can rescue defective fork restart, but is incapable of rescue when FANCD2 is simultaneously depleted by siRNA ([Figure 2B](#fig2){ref-type="fig"}). The ability of PolK to promote fork restart also strongly correlated with longer track lengths of DNA synthesis after HU wash off (quantifying the length of the red tracks only in fork events containing both green and red tracks) ([Figure 2B](#fig2){ref-type="fig"}). Taken together, these data suggest that PolK-mediated fork restart requires the activation of the FA pathway.

![PolK functions in concert with the FA pathway to promote replication fork restart.\
(**A**) Quantification of fork restart efficiency in FANCD2-deficient patient cells (PD20) complemented with either vector only, FANCD2 WT, or K561R mutant in the presence or absence of PolK siRNA and treated as indicated. PD20 (vector only) cells were treated with 300 nM Chk1i (AZD7762) throughout the duration of HU and CldU time points as a positive control for the detection of elevated fork-stalling events. Western blot analysis showing siRNA knockdown efficiency in PD20 cells. (**B**) Quantification of fork restart efficiency in 293T CRISPR PolK (sgPolK) cells complemented with either empty vector or GFP-PolK WT in the presence or absence of FANCD2 siRNA and treated as indicated. CldU (red) tract length measurements of restarted forks determine the varying degree of individual fork restart events. Western blot analysis showing expression and siRNA knockdown efficiency in sgPolK 293 T cells. Data for % stalled forks are represented by mean ± s.d. of three independent experiments and p-values calculated using t-test with Welch's correction. Data for tract length measurements are plotted from three independent experiments with mean ± s.e.m. and p-values calculated using Mann-Whitney t-test. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.](elife-41426-fig2){#fig2}

Loss of PolK does not affect replication checkpoint response or recovery {#s2-3}
------------------------------------------------------------------------

Next, we wanted to determine whether the failure to properly restart forks in PolK-deficient cells would somehow impact the replication checkpoint response or recovery by monitoring both Chk1 and RPA phosphorylation levels in response to HU treatment. A previous study showed that PolK was important for facilitating Chk1 phosphorylation in response to replication stress ([@bib8]). Surprisingly, using our experimental setting, both ATR-dependent Chk1 phosphorylation on Ser345 or RPA32 phosphorylation on Ser33 (or Ser4/8) were unaffected by the loss of PolK or FANCD2 ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) in different cell lines. Even in the 293T *PolK* CRISPR clone (sgPolK clone \#1), the reconstitution of GFP-PolK WT did not alter the kinetics of checkpoint recovery of phosphorylated Chk1 or RPA after HU wash off ([Figure 3B](#fig3){ref-type="fig"}). However, the levels of PCNA monoubiquitination (mUb-PCNA) was higher in the GFP-PolK WT-expressing sgPolK clone \#1 293 T cells in comparison to the vector control cells ([Figure 3B](#fig3){ref-type="fig"}). As PolK has been previously shown to directly interact with mUb-PCNA ([@bib25]; [@bib21]), this suggests that expression of PolK may help stabilize mUb-PCNA in response to HU treatment.

![PolK interacts with K48-linked polyubiquitinated PCNA via its UBZ domains in a HU-dependent manner.\
(**A**) Western blot analysis of RPE-1 cells treated with the indicated siRNAs and HU (2 mM) time-points. (**B**) Western blot analysis of 293T sgPolK cells complemented with either empty vector or GFP-PolK WT and pulsed with HU (2 mM) for 4 hr before wash step and recovery for the indicated time-points. (**C**) Schematic diagram showing domains of PolK. Formaldehyde-induced crosslinking of 293T sgPolK cells treated with HU (2 mM) for 4 hr as indicated. Extracts from cells complemented with either empty vector, GFP-PolK WT or a double ubiquitin-binding domain mutant (UBZ) of GFP-PolK were then subjected to anti-GFP pulldown, followed by Western blot analysis with the indicated antibodies. (**D**) Ubiquitin chain restriction digest analysis using similarly treated and immunoprecipitated (IP) samples as in (**C**) to enrich for polyubiquitinated PCNA that is bound by GFP-PolK and induced by HU. Samples on beads were then incubated with 900 ng of indicated recombinant DUBs for 1 hr at 37°C prior to Western blot analysis with the indicated antibodies (upper and lower panels). SARS PLpro catalytic mutant (C112A) was used for negative control as indicated (lower panel). (**E**) Quantification of fork restart efficiency in 293T sgPolK cells complemented with either empty vector, GFP-PolK WT, Catalytic-Dead (CD), or ubiquitin-binding mutant (UBZ). CldU (red) tract length measurements of restarted forks were determined for WT and the different PolK mutants. (**F**) Quantification of fork restart efficiency in U2OS cells treated with PCNA siRNA and complemented with siRNA-resistant HA-tagged PCNA-WT or ubiquitin site mutant HA-PCNA K164R. Western blot analysis showing exogenously expressed siRNA-resistant HA-PCNA in U2OS cells. Data for % stalled forks are represented by mean ± s.d. of three independent experiments and p-values calculated using t-test with Welch's correction. Data for tract measurements are plotted from three independent experiments with mean ± s.e.m. and p-values calculated using Mann-Whitney t-test. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.](elife-41426-fig3){#fig3}

PolK interacts with K48-linked polyubiquitinated PCNA in HU-treated cells {#s2-4}
-------------------------------------------------------------------------

To determine whether PolK interacts with mUb-PCNA in response to HU treatment, we used a formaldehyde-crosslinking and immunoprecipitation (IP) technique ([@bib26]) to capture transiently associated proteins on PolK. We found that GFP-tagged PolK WT, but not mutations of both UBDs (UBZ mutant), was able to interact with mUb-PCNA in an HU-dependent manner ([Figure 3C](#fig3){ref-type="fig"}). However, the interaction of PolK with FANCD2, FANCI, RPA, or even unmodified PCNA, was not HU-inducible, nor was it dependent on its UBDs ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). A commercially available antibody against mUb-PCNA was used both for western blot analysis and crosslink-IP to verify that PolK interacts with mUb-PCNA in a manner that is dependent on its UBDs ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). The detection of additional higher molecular weight mUb-PCNA antibody-reactive bands in the anti-GFP antibody pull-down assay suggests that PolK is likely interacting with differentially polyubiquitinated (di- or tri-ubiquitinated) forms of PCNA ([Figure 3C](#fig3){ref-type="fig"}). Although several studies suggest that DNA damage-induced polyubiquitination of PCNA is primarily composed of K63-linked Ub chains ([@bib31]; [@bib14]), it is unclear whether HU-induced polyubiquitinated PCNA follows the same rule. To characterize the nature of the ubiquitin chain linkage on PCNA, polyubiquitinated PCNA was enriched and purified from HU-treated cells using either the anti-GFP or mUb-PCNA antibody pulldown assay ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) and the isolates were subjected to an in vitro ubiquitin chain restriction analysis ([@bib37]). Surprisingly, when using a purified SARS-PLpro deubiquitinating (DUB) enzyme that exclusively cleaves longer K48-linked ubiquitin chains (but not monoubiquitinated substrates) ([@bib6]; [@bib5]), the higher molecular weight species of PCNA (likely di- or triUb-PCNA) were greatly reduced when incubated with PLpro WT, but not its catalytic mutant (C112A) or the AMSH K63 chain cleavage-specific metalloprotease ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). For positive control, the catalytic domain of the ubiquitin protease USP2 was able to non-specifically cleave both the monoUb- and diUb-PCNA bands in the assay ([Figure 3D](#fig3){ref-type="fig"}). The ubiquitin chain linkage specificity of the different recombinant DUBs tested here was reconfirmed using an in vitro cleavage assay of either K48 or K63 tri-Ub unanchored chains as substrates ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). Using this in vitro ubiquitin chain restriction analysis, it supports the notion that PolK mostly interacts with K48-linked polyubiquitinated PCNA in HU-treated cells.

Since the UBDs of PolK is required for the recruitment of PolK to polyubiquitinated PCNA in response to HU treatment, we next asked whether the UBDs of PolK is required for proper fork restart. Using the CRISPR sgPolK cells that are transiently transfected with either GFP-tagged PolK WT or the UBZ mutant, we showed that the ubiquitin-binding capacity of PolK is required for PolK-mediated fork restart ([Figure 3E](#fig3){ref-type="fig"}). Importantly, the catalytically dead (CD) mutant of PolK (DE198/199AA) was also unable to properly perform fork restart. This demonstrates that both the DNA polymerase activity and ubiquitin-mediated transactions (likely through polyubiquitinated PCNA) are essential for PolK-dependent recovery of stalled replication forks ([Figure 3E](#fig3){ref-type="fig"}). In line with the requirement of the UBDs of PolK for proper fork restart, we also showed that the ubiquitination mutant (K164R) of PCNA has compromised fork restart after HU treatment ([Figure 3F](#fig3){ref-type="fig"}).

PolK protects forks against SMARCAL1- and MRE11-dependent nascent DNA degradation {#s2-5}
---------------------------------------------------------------------------------

Replication forks that stall after encountering DNA lesions or during conditions of high dose HU treatment may undergo an intermediate fork reversal step to help promote fork protection ([@bib64]; [@bib62]). The regressed arm of a reversed fork resembles a one-ended double-strand break (DSB) and must be properly protected against nucleolytic degradation of nascent DNA. Previous studies demonstrated the requirement of the FA pathway and other HDR proteins, such as Rad51 and the breast cancer susceptibility proteins BRCA1 and BRCA2, for the protection of stalled forks against nascent DNA degradation ([@bib49]; [@bib48]). Whether PolK plays a role in fork protection is unknown. To directly measure the extent of nascent DNA degradation of a stalled fork by DNA fiber analysis, we modified the labeling procedure whereby IdU and CldU are first sequentially pulse-labeled, followed by washes and treatment with high dose HU (2 mM) for 4 hr; the red 2nd color track lengths (CldU) were measured to determine the level of nascent DNA degradation (see schematics in [Figure 4A](#fig4){ref-type="fig"}). In agreement with previous findings ([@bib49]; [@bib48]; [@bib44]), we showed that FANCD2 and other HDR-related factors, Rad51 and BRCA2, are required for fork protection ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A,C and D](#fig4s1){ref-type="fig"}). However, in contrast to FANCD2, both Rad51 and BRCA2 are not required for efficient fork restart ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). This suggests that mechanisms involving HDR to prevent fork collapse, such as fork reversals, are separable from fork restart as defined by our HU treatment conditions.

![PolK prevents MRE11-dependent nascent DNA degradation.\
(**A**) Schematic for measuring nascent DNA degradation (shortened CldU-labeled tracts) by DNA fiber analysis (**A--C,E**). Quantification of nascent DNA degradation (changes in CldU tract lengths) in 293 T cells treated with the indicated siRNAs. (**B**) Quantification of nascent DNA degradation in 293T sgPolK cells that were complemented with either empty vector, GFP-PolK WT or the indicated GFP-PolK mutants. (**C**) Quantification of nascent DNA degradation in 293T sgPolK cells complemented with either empty vector or GFP-PolK WT were treated with or without Mre11 inhibitor, Mirin (50 μm), in the presence of HU as indicated. (**D**) Quantification of fork restart efficiency in RPE-1 cells with the indicated siRNAs and treated with or without Mirin (50 μM) in the presence of HU (2 mM) as indicated. (**E**) Quantification of nascent DNA degradation in parental 293T or 293T sgPolK cells treated with the indicated siRNAs. (**F**) Quantification of fork restart efficiency in parental 293T or 293T sgPolK cells treated with the indicated siRNAs. Data for % stalled forks are represented by mean ± s.d. of three independent experiments and p-values calculated using t-test with Welch's correction. Data for tract length measurements are plotted from three independent experiments with mean ± s.e.m. and p-values calculated using Mann-Whitney t-test. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.](elife-41426-fig4){#fig4}

As both PolK and FANCD2 function in the same pathway to mediate fork restart, we next tested whether PolK could also have a role in fork protection. Similar to a FANCD2 loss, we found that PolK depletion caused a reduction in the nascent DNA tract length ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Additionally, expression of GFP-PolK WT back into the CRISPR sgPolK cells can reverse nascent DNA degradation in HU-treated cells ([Figure 4B](#fig4){ref-type="fig"}). Intriguingly, the expression of the CD mutant, but not the UBZ mutant of PolK, can still partially rescue PolK deficiency in preventing nascent DNA degradation ([Figure 4B](#fig4){ref-type="fig"}). This may be due to the fact that the inactive form of PolK is still present in the cells and may bind with high affinity to the nascent DNA, thereby blocking access of nucleases (or other fork remodeling proteins) to the nascent DNA for degradation. This argues that the polymerase activity is not as critical for preventing nascent DNA degradation as it is for mediating fork restart efficiency, thus revealing a possible mechanistic difference between PolK's role in fork restart *versus* fork protection. It is noted that the expression of the UBZ mutant has a marginally more severe phenotype than vector control, implying that the UBZ mutant may still interact with PCNA or some other factor(s) that could lead to increased nascent DNA degradation.

The MRE11 nuclease was previously shown to be critical for nascent DNA degradation of stalled replication forks in FA pathway- or BRCA2-deficient cells ([@bib49]; [@bib48]). Recent data also suggests that the SNF2-family of fork remodelers, such as SMARCAL1, acts upstream of MRE11 and is responsible for the processing of stalled forks to the reversed fork structure, enabling MRE11-dependent nucleolytic degradation of nascent DNA ([@bib56]). To test whether MRE11 or SMARCAL1 is responsible for mediating nascent DNA degradation in PolK-deficient cells, we treated CRISPR sgPolK cells with either mirin to inhibit MRE11 nuclease activity or with an siRNA against SMARCAL1 during HU treatment. Both mirin treatment and SMARCAL1 knockdown reversed the nascent DNA degradation observed in HU-treated PolK-deficient cells ([Figure 4C,E](#fig4){ref-type="fig"}). Since we showed that PolK perform dual functions in both fork protection and fork restart, it is unknown whether these two events are functionally connected. For example, would the rescue of fork protection in PolK-deficient cells with either mirin treatment or SMARCAL1 depletion alter the efficiency of fork restart? Remarkably, inhibition of either MRE11 activity or SMARCAL1 had no effect on fork restart after HU treatment ([Figure 4D,F](#fig4){ref-type="fig"}). This implies that PolK is capable of rescuing stalled forks via two non-overlapping mechanisms: 1) fork protection against SMARCAL1- and MRE11-dependent nucleolytic degradation, and 2) replication fork restart.

PolK-mediated DNA synthesis during conditions of nucleotide starvation {#s2-6}
----------------------------------------------------------------------

Past studies have suggested that PolK can cause a reduction in replication fork speed when it becomes aberrantly recruited to the replication fork by either the loss of USP1 or p21^CDKN1A^ in untreated cells ([@bib25]; [@bib36]). Indeed, by DNA fiber analysis, we show that the tract length is slightly elevated (faster fork speed) in the absence of PolK, while USP1 knockdown can lead to a PolK-dependent slow-down of the replication fork in the absence of HU treatment, as demonstrated in our previous study ([@bib25]) ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Thus, in unperturbed, dividing cells, the aberrant recruitment of PolK to the replication fork can lead to reduced DNA synthesis and genomic instability ([@bib25]; [@bib36]), which is likely due, in part, to the slowing of the normal fork speed. However, it is unclear whether PolK plays an important role in DNA synthesis during conditions of nucleotide deprivation. Cells treated with high-dose HU (2 mM or higher) dramatically reduces, but does not completely abolish, DNA synthesis ([@bib16]). For instance, in bacteria, Y-family DNA Pols have the potential to operate efficiently at low dNTP concentrations in comparison to the replicative DNA Pols due to intrinsic differences in K~m~ values for dNTPs ([@bib20]). The slower fork movement in HU-treated cells can be monitored by DNA fiber analysis using a longer labeling time for CldU (see labeling schematics in [Figure 5A](#fig5){ref-type="fig"}). We found that PolK depletion further reduced DNA synthesis (or fork speed) during HU treatment, as measured by reduced CldU tract length adjacent to IdU tracts ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

![PolK-dependent DNA synthesis in the presence of HU.\
(**A**) Schematic for measuring replication fork speed (CldU tract length) under HU treatment for 4 hr. To ensure that the CldU-labeled DNA was under constant high dose HU treatment, cells were pre-treated with 2 mM HU for 40 min prior to the addition of CldU in the presence of HU for 4 hr. Quantification of fork speed in RPE-1 cells treated with the indicated siRNAs. (**B**) Schematic of a modified iPOND assay to measure proteins associated with the replisome under nucleotide starvation conditions. Similar to (**A**), 293 T cells were either left untreated or pretreated with HU (2 mM) for 40 min prior to the addition of EdU (10 μM) in the presence of HU for 4 hr. Cells were then either collected immediately (EdU samples) or chased with Thymidine (10 μM) for 1 hr (EdU + chase) in the presence or absence of HU. Samples without HU were treated for only 10 min with EdU or chased with Thymidine for 1 hr. Western blot analysis showing the biotin-streptavidin pulldown after click-reaction in parental 293 T cells and probed with the indicated antibodies. (**C**) Schematic for measuring EdU incorporation intensity by direct fluorescence measurements in HU-treated cells. U2OS sgPolK cells were complemented with either empty vector, GFP-PolK WT, GFP-PolK mutant constructs, or different Y-family TLS Pols, GFP-Pol eta or GFP-Pol iota. Cells were pretreated with HU (2 mM) for 1 hr, prior to the addition of EdU (10 μM) in the presence of HU for 4 hr. Mean EdU intensity per nucleus measured by ImageJ were plotted from three independent experiments. (**D**) Single-molecule localization imaging of EdU signal distribution per foci or nuclei. RPE-1 cells were treated with the indicated siRNAs prior to pretreatment with HU (2 mM) for 1 hr, followed by the addition of EdU in the presence of HU for 4 hr. Representative super-resolution images of nuclei with EdU signal in magenta are shown. Quantification of EdU foci counts per nuclei and amount of EdU counts per foci are plotted from three independent experiments. (**E**) U2OS sgPolK cells complemented with either GFP-PolK WT or GFP-PolK CD were pulse-labeled with EdU and treated with HU (2 mM) or not (NT). Treatment conditions and quantification of EdU foci per nuclei by super-resolution imaging techniques were done as in (**D**). (**F**) Quantification of fork restart efficiency in RPE-1 cells treated with the indicated siRNAs whereby 'restarted' forks are measured as previously elongating forks (IdU tracts) that become converted to CldU tracts in the presence of HU (2 mM). Cells were pretreated with HU for 40 min prior to the addition of CldU for 4 hr to ensure that CldU pulse-labeled cells were already under constant high-dose HU treatment. (**G**) Quantification of fork restart efficiency in RPE-1 cells treated with the indicated siRNAs whereby IdU pulse-labeled forks under constant HU treatment are measured to determine whether they can be 'restarted' after HU wash off (CldU pulse-label). Data for % stalled forks and quantification of EdU foci counts by single-molecule localization imaging are represented by mean ± s.d. of three independent experiments and p-values calculated using t-test with Welch's correction and indicated above the plots. Data for tract length measurements are plotted from three independent experiments with mean ± s.e.m. and p-values calculated using Mann-Whitney t-test. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.\
10.7554/eLife.41426.015Figure 5---source data 1.EdU intensity per nucleus.](elife-41426-fig5){#fig5}

The slower fork movement in HU-treated cells is likely not due to unscheduled replication-transcription conflicts as treatment with an inhibitor of the elongation step during RNA Pol II transcription, 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), which is known to reduce replication-transcription conflicts leading to R-loop formation ([@bib28]; [@bib35]), had no effect on tract length (fork speed) under high-dose HU (2 mM) treatment ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}) in control or PolK-depleted samples. Consistent with this result, treatment of RPE-1 cells with either DRB or flavopiridol (FVP) ([@bib7]) in the presence or absence of PolK did not cause any changes to HU-mediated checkpoint activation ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}).

Previous studies showed that FANCD2 is necessary for actively restraining DNA synthesis upon nucleotide deprivation ([@bib33]; [@bib13]; [@bib39]). In FANCD2-depleted cells, the faster fork speed (longer CldU tracts) in the presence of HU is largely dependent on PolK ([Figure 5A](#fig5){ref-type="fig"}). Inhibition of MRE11 activity by mirin did not affect the average tract lengths in PolK- or FANCD2-depleted cells ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), suggesting that aberrant nuclease activity acting on deprotected or reversed forks does not account for changes in DNA synthesis levels (fork speed) during nucleotide starvation conditions. One interpretation of these results is that the reduced DNA synthesis during HU treatment in PolK-depleted cells could be due to a defect in fork restart, such that during the time of HU treatment, replication forks will continuously stall and restart and the reduced efficiency of restart associated with the loss of PolK could lead to shorter CldU tracts. While we cannot formally rule out this possibility, we do not favor this model based on our evidence that even though both PolK- and FANCD2-depleted cells have fork restart defects ([Figure 2](#fig2){ref-type="fig"}), the loss of FANCD2 showed an increase in CldU synthesis during HU treatment ([@bib33]; [@bib13]), which is the opposite of what has been observed in PolK-deficient cells ([Figure 5A](#fig5){ref-type="fig"}). This lack of correlation between fork restart and HU-mediated DNA synthesis will be addressed below ([Figure 5F,G](#fig5){ref-type="fig"}).

Isolation of protein on nascent DNA (iPOND) is a powerful technique to identify proteins bound to nascent DNA in the vicinity of the replisome during unperturbed replication ([@bib53]). To determine whether PolK directly interacts with the replisome in HU-treated cells, we modified the iPOND protocol by pretreating cells with HU to slow DNA synthesis prior to labeling with the nucleotide analog 5-Ethynyl-2'-deoxyuridine (EdU) in the same media. After click chemistry with biotin, followed by streptavidin beads pull-down, we showed that both PolK and FANCD2 were significantly enriched in the replisome of HU-treated samples, but not present in thymidine-chased samples ([Figure 5B](#fig5){ref-type="fig"}).

After showing that PolK was directly bound to EdU-labeled nascent DNA, we wanted to determine whether EdU labeling efficiency can be utilized as an additional measurement for DNA synthesis during HU treatment. We pulse-labeled cells with EdU and measured differential EdU fluorescent intensity in U2OS cells (see schematics in [Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). It is noted that due to the high level of EdU incorporation under normal DNA synthesis, the change in EdU intensity per nuclei could not be observed in PolK-deficient cells unless cells were pretreated with HU prior to the EdU labeling step under HU treatment ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). In CRISPR sgPolK U2OS cells, the expression of PolK WT, but not the CD or UBZ mutant, promoted DNA synthesis during HU treatment ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2C--E](#fig5s2){ref-type="fig"}). This was not due to the over-compensation of any TLS Pols as expression of other Y-family TLS Pols, such as Pol eta or iota, could not compensate for the reduced DNA synthesis in PolK-deficient cells under HU treatment ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}). Thus, amongst the different TLS Pols in mammalian cells, PolK possesses a unique role in facilitating DNA synthesis under conditions of nucleotide starvation.

Since PolK-dependent DNA synthesis is largely restricted by the presence of FANCD2 in HU-treated cells ([Figure 5A](#fig5){ref-type="fig"}), we wanted to explore whether the organization of EdU-incorporated nuclear foci is affected by the presence or absence of PolK and/or FANCD2. To quantify the EdU incorporation per nucleus as well as within each replication focus, we employed single-molecule stochastic blinking super-resolution imaging ([@bib46]) of fluorescently labeled EdU along with unbiased Pair-Correlation Function analysis (see Materials and methods) ([@bib51]; [@bib60]). This approach enabled us to map the precise molecular coordinates of EdU molecules within a cell with a resolution of \~9 nm, and extract robust metrics such as the exact amount of EdU foci incorporated per nucleus as well as the amount of EdU content within each focus. Using a labeling scheme to measure HU synthesis (1 hr pretreatment with 2 mM HU, followed by the addition of 10 μM EdU to HU medium), we observed that the total number of foci and the amount of EdU counts per foci are both reduced in PolK-depleted cells ([Figure 5D](#fig5){ref-type="fig"}). This suggests that PolK has a role in maintaining the total number of active forks per nucleus that is able to synthesize under low nucleotide conditions, in addition to a reduction of synthesis at individual forks. While the number of EdU foci per nucleus is reduced in PolK-depleted cells, this could be rescued when FANCD2 was depleted concomitantly ([Figure 5D](#fig5){ref-type="fig"}). This suggests that in the absence of PolK, the loss of FANCD2 may enable additional forks (more EdU foci per nucleus) to undergo DNA synthesis in the presence of HU. Thus, FANCD2 may behave as a general restriction factor against aberrant DNA synthesis in response to replication stress. Addressing this point in the future may require DNA locus-specific or genome-wide analysis of fork restart differences within PolK- and/or FANCD2-deficient background. However, the EdU counts per foci (EdU molecule intensity of individual foci) remains decreased in the absence of PolK, irrespective of FANCD2 levels ([Figure 5D](#fig5){ref-type="fig"}). This implies that while forks that may incorporate EdU independently of PolK, it will still do so at a reduced efficiency (less EdU counts per foci). In the absence of FANCD2, the EdU counts per foci is not elevated above control levels. Since the loss of FANCD2 led to longer tract lengths using DNA fiber assays ([Figure 5A](#fig5){ref-type="fig"}), this would imply that the EdU counts per foci observed by super-resolution imaging is qualitatively distinct from tract lengths generated by individual forks. What is the exact nature of these EdU counts per foci remains to be determined. Neverthless, the EdU foci counts per nuclei that is generated by PolK is still dependent on its catalytic activity ([Figure 5E](#fig5){ref-type="fig"}). Cross-Pair-Correlation analysis between GFP-PolK and EdU signal was done to ensure that differences observed in EdU foci counts per nucleus were only observed under HU treatment, irrespective of differences in GFP-PolK WT or CD expression levels ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}).

Next, we tested whether PolK-dependent DNA synthesis under HU is functionally linked to fork restart. Modifying our DNA fiber analysis (see schematics in [Figure 5F](#fig5){ref-type="fig"}), we first determined how many of the elongating forks (labeled by IdU, no treatment) remained 'moving' (albeit at a slower velocity) when exposed to HU (pretreated with HU, followed by labeling with CldU for a 4 hr HU treatment). Applying this labeling schematic, the loss of PolK or FANCD2 recapitulated the fork restart defect observed originally when fork restart was measured after HU wash off ([Figure 5F](#fig5){ref-type="fig"}). Next, we determined how many of the slow-moving forks during HU treatment are converted to restarted forks once HU has been removed. Surprisingly, greater than 95% of the slow-moving forks (pretreated with HU, followed by labeling with IdU for a 4 hr HU treatment) were converted to fast-moving restarted forks (labeled by CldU after HU wash off) irrespective of PolK or FANCD2 deficiency ([Figure 5G](#fig5){ref-type="fig"}). In summary, the defect in fork restart efficiency in either PolK- or FANCD2-depleted cells occurs at a much earlier point during the transition from normal elongating forks in untreated cells into slower-moving forks under HU treatment ([Figure 5F](#fig5){ref-type="fig"}, see working model in [Figure 6D](#fig6){ref-type="fig"}). Even though less forks are able to resume progression (restart) after pulsing with HU in either PolK- or FANCD2-deficient cells, the remaining forks that are competent to undergo DNA synthesis under HU independently of PolK, appears to be fully proficient to resume normal DNA synthesis once HU is removed.

![Loss of PolK leads to a p53-dependent cell cycle delay and 53BP1 nuclear body accumulation following HU pulse treatment.\
(**A**) Schematic for measuring cell cycle progression after recovery from HU pulse treatment (**A--C**). RPE-1 cells treated with the indicated siRNAs were initially pulsed-labeled with EdU (10 μM) for 1 hr to label untreated S-phase cells, followed by a wash step, an HU (2 mM) pulse treatment for 4 hr, another wash step, and recovery (chase) with fresh media for the indicated time. Recovery of EdU-positive, HU pulse-treated cells were tracked by FACS analysis and the proportion of cells in different cell cycle phases were determined by DAPI DNA content (FlowJo). Data represented from three independent experiments with mean ± s.d (**A**). (**B**) RPE-1 cells treated with the indicated siRNAs were treated with HU (4 hr), followed by a wash step, and chase for 24 hr with fresh media. Cells were then fixed and stained for SA-β-Gal activity. Data represented from three independent experiments with mean ± s.d., p-value calculated using t-test with Welch's correction. (**C**) RPE-1 cells treated with the indicated siRNAs were treated with HU (4 hr), followed by a wash step, and chase for 18 hr with fresh media. Cells were then fixed and co-stained for Cyclin A and 53BP1. Only Cyclin A-negative RPE-1 cells (G1 phase) were quantified for 53BP1 nuclear bodies. Data represented from three independent experiments with a minimum of 300 Cyclin A-negative cells per experiment; mean ± s.d. was plotted and p-value calculated using t-test with Welch's correction. (**D**) A model depicting how PolK promotes replication stress recovery and genome stability in an FA pathway-dependent manner in response to conditions of nucleotide starvation. n.s. = no significance, \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001.\
10.7554/eLife.41426.018Figure 6---source data 1.Source data for [Figure 6C and B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B and C](#fig6s1){ref-type="fig"}.](elife-41426-fig6){#fig6}

PolK promotes cell cycle recovery after replication stress {#s2-7}
----------------------------------------------------------

In this study, we have uncovered several unique properties for PolK in alleviating replication stress. Despite significant defects in replication fork protection and fork restart in response to HU treatment, the phenotype in *PolK*-deficient mice in the absence of perturbations is relatively mild ([@bib10]; [@bib55]). Asynchronous growing PolK-deficient cells have a normal cell cycle progression in comparison to control cells ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). They also do not experience higher levels of DNA damage or cell cycle checkpoint activation in response to HU and HU wash off ([Figure 3A,B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). To reveal a subtler, replication-associated defect, we interrogated how the cells are able to progress and recover from a short-term (4 hr) HU pulse treatment in a time-course study. Using EdU pulse-chase cell cycle analysis to directly visualize the progression of a fluorescently labeled S-phase population into the next cell cycle phase, we observed a prolonged S-phase and a reduced G2 phase in PolK-deficient cells in comparison to control cells ([Figure 6A](#fig6){ref-type="fig"}). PolK-depleted cells also developed elevated senescence-associated β-galactosidase (SA-βgal) activity after a short-term HU treatment, followed by a 24 hr chase ([Figure 6B](#fig6){ref-type="fig"}). Importantly, depletion of p53 was capable of reversing both cell cycle delay (data not shown) and SA-βgal activity in PolK-deficient cells ([Figure 6B](#fig6){ref-type="fig"}). Elevated levels of 53BP1 nuclear bodies in G1 phase cells (Cyclin A-negative) were also observed in PolK-deficient cells after a short-term HU treatment, followed by an 18 hr chase ([Figure 6C](#fig6){ref-type="fig"}), suggesting that the cause of cell cycle defects is likely due to the gradual accumulation of replication-associated DNA damage that become shielded within 53BP1 nuclear bodies for repair in the next G1 phase ([@bib34]; [@bib22]). The replication-induced DNA damage phenotype shown in PolK-deficient cells is comparable to those experienced in FANCD2-depleted cells ([@bib11]) ([Figure 6A--C](#fig6){ref-type="fig"}). Importantly, the siRNA depletion of both Polk and FANCD2 simultaneously yielded similar levels of elevated SA-βgal activity and 53BP1 nuclear bodies as either of the individual siRNA depletions, suggesting that both of these proteins act within the same pathway ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Significantly, mirin treatment to prevent nascent DNA degradation during the HU pulse treatment did not alter the levels of 53BP1 nuclear bodies ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), suggesting that the replication-associated problems based on the loss of PolK and/or FANCD2 is caused by defects in fork restart efficiency, and not fork protection (MRE11-dependent nascent DNA degradation). Thus, both PolK and the FA pathway cooperate within the same network that resolves replication stress from improperly stalled forks to help maintain genome integrity.

Discussion {#s3}
==========

Studies have indicated the existence of tumorigenesis barriers that slow or inhibit the progression of preneoplastic lesions to neoplasia. One such barrier involves oncogene-induced DNA replication stress, which leads to activation of the DNA damage checkpoint, cell cycle arrest and/or senescence and apoptosis ([@bib50]; [@bib19]; [@bib41]). We propose that early deregulation of the replication stress response could lead to sub-lethal genomic instability that becomes progressively worse in subsequent rounds of cell division as cells escape oncogene-induced senescence. Thus, it is critical to understand the different mechanisms that govern replication fork recovery upon exposure to replication stress conditions. Based on our studies, we predict that a wide range of nucleotide starvation conditions, including oncogene-induced nucleotide exhaustion, could lead to a dependence on PolK and/or the FA pathway to help mammalian cells withstand limited nucleotide availability via mechanisms involving fork restart. Interestingly, a recent study by Vaziri and colleagues showed that PolK confers tolerance to oncogenic replication stress ([@bib63]). Thus, we postulate that under certain conditions of low dNTP levels, the normal replicative polymerases (delta, epsilon) are disfavored in their usage while TLS Pols can readily engage at the stalled replication fork due to the low nucleotide concentration. This concept was originally proposed by Walker and colleagues, showing that the bacterial Y-family DNA polymerases Pol IV (DinB) and Pol V (UmuD~2~'C) enhance cell survival under conditions of nucleotide starvation ([@bib20]). Additionally, PolK has been shown to be intrinsically more processive and has higher fidelity than the other Y-family TLS Pols ([@bib32]). The stabilization of the replisome by PolK during HU treatment provides at least two major advantages: 1) fork stalling events that lead to reversed fork structures would remain protected against MRE11-dependent nuclease digestion of nascent DNA, and 2) a moving fork (albeit slower-moving) provides a reasonable temporary solution or surrogate prior to the eventual resumption of normal DNA synthesis for fork restart after nucleotide levels rise again, leading to a more efficient fork recovery process ([Figure 6D](#fig6){ref-type="fig"}). We speculate that the usage of PolK and other related processes may not be entirely stochastic, but are likely invoked at vulnerable regions of the genome. Uncovering the different mechanisms of fork recovery may help provide a clearer picture of how timely completion of DNA replication at the genome-wide level is required to prevent genome instability, and how these factors, including PolK and the FA pathway, can act as barriers against early stage carcinogenesis.

Previous studies have implicated both TLS Pol Eta (PolH) and PolK to complete DNA replication at common fragile sites (CFSs) ([@bib3]; [@bib45]). A recent work from Nussenzweig and colleagues mapped genome-wide DNA break sites in response to prolonged HU-mediated replication stress in mammalian cells ([@bib59]). Remarkably, they found that long poly(dA:dT) DNA tracts are preferred sites of replication fork stalling and collapse within early-replicating fragile sites (ERFSs) and late-replicating common fragile sites (CFSs). Intriguingly, they discovered a PolK mutational signature ([@bib23]) at these fragile poly(dA:dT) DNA structures, suggesting that throughout evolution, PolK has been employed during replication of these poly(dA:dT) repeats at these replication fork-stalling sites. Thus, in our study, we provide a mechanistic insight into how PolK is recruited and utilized at stalled replication forks to aid in fork recovery. Implications of PolK's role in both genome maintenance and mutagenesis will be highly relevant in recurrent chromosomal rearrangements that arise from breakage within fragile hotspot regions throughout cancer genomes, as well as progression of preneoplastic lesions to genomicaly unstable cancers.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource       Designation                                 Source or reference              Identifiers                                                    Additional\
                                                                                                                                                                                       information
  ---------------------------------------- ------------------------------------------- -------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Cell line\                               hTERT RPE-1\                                ATCC                             CRL-4000                                                       
  (*Homo sapiens*)\                        (RPE)                                                                                                                                       
  female                                                                                                                                                                               

  Cell line\                               U-2 OS (U2OS)                               ATCC                             HTB-96                                                         
  (*Homo sapiens*)\                                                                                                                                                                    
  female                                                                                                                                                                               

  Cell line\                               U2OS PolK KO (U2OS sgPolK\                  This Paper                                                                                      CRISPR-Cas9 generated using pX330 construct and guide RNAs listed in Materials and methods.
  (*Homo sapiens)* female                  Clone \#1)                                                                                                                                  

  Cell line (*Homo sapiens*)               293T                                        ATCC                             CRL-3216                                                       

  Cell line (*Homo sapiens*)               293T PolK KO \#1 (sgPolK Clone \#1)         This Paper                                                                                      CRISPR-Cas9 generated using pX330 construct and guide RNAs listed in Materials and methods.

  Cell line (*Homo sapiens*)               293T PolK KO \#2 (sgPolK Clone \#2)         This Paper                                                                                      CRISPR-Cas9 generated using pX330 construct and guide RNAs listed in Materials and methods.

  Cell line (*Homo sapiens*)               PD20 Vector                                 PMID: 11239454                                                                                  [@bib17]

  Cell line\                               PD20 FANCD2 WT                              PMID: 11239454                                                                                  [@bib17]
  (*Homo sapiens*)                                                                                                                                                                     

  Cell line\                               PD20 FANCD2\                                PMID: 11239454                                                                                  [@bib17]
  (*Homo sapiens*)                         K561R                                                                                                                                       

  Transfected construct (*Homo sapiens*)   pCDNA3.1 HA-\                               PMID: 22157819                                                                                  [@bib15]
                                           PCNA WT                                                                                                                                     

  Transfected construct\                   pCDNA3.1 HA-\                               PMID: 22157819                                                                                  [@bib15]
  (*Homo sapiens*)                         PCNA K164R                                                                                                                                  

  Recombinant DNA reagent                  eGFP-C1                                     ClonTech                                                                                        

  Transfected construct (*Homo sapiens*)   eGFP-C1-PolK WT                             PMID: 22157819                                                                                  [@bib15]

  Transfected construct (*Homo sapiens*)   eGFP-C1-PolK CD                             This Paper                                                                                      Site directed mutagenesis using primers listed in Materials and methods. D198A/E199A

  Transfected construct (*Homo sapiens*)   eGFP-C1-PolK UBZ                            This Paper                                                                                      Site directed mutagenesis using primers\
                                                                                                                                                                                       listed in Materials and methods. D644A/D799A

  Transfected construct (*Homo sapiens*)   eGFP-C1-PolH WT                             \                                                                                               
                                                                                       [@bib15]\                                                                                       
                                                                                       [@bib15] PMID: 22157819                                                                         

  Transfected construct (*Homo sapiens*)   eGFP-C1-PolI WT                             [@bib16] PMID: 22157819                                                                         

  Recombinant DNA reagent                  pX330                                       Addgene                          \#42230                                                        

  Antibody                                 Mouse anti-IdU                              BD Bioscience                    Cat. \#: 347580                                                IF (1:200)

  Antibody                                 Rat anti-CldU                               Abcam                            Cat. \#: ab6326                                                IF (1:100)

  Antibody                                 Mouse anti-PCNA                             Abcam                            Cat. \#: ab29                                                  WB (1:5000)

  Antibody                                 Rabbit anti-PCNA-Ub                         Cell Signaling                   Cat. \#: D5C7P                                                 WB (1:1000)

  Antibody                                 Mouse anti-\                                Santa Cruz                       Cat. \#: sc-20022                                              WB (1:500)
                                           FANCD2                                                                                                                                      

  Antibody                                 Rabbit anti-\                               Novus Biological                 Cat. \#: NB100-182                                             WB (1:5000)
                                           FANCD2                                                                                                                                      

  Antibody                                 Rabbit anti-pCHK1 S345                      Cell Signaling                   Cat. \#: 133D3                                                 WB (1:5000)

  Antibody                                 Goat\                                       Abcam                            Cat. \#: ab2845                                                WB (1:5000)
                                           anti-CHK1                                                                                                                                   

  Antibody                                 Mouse\                                      EMD Millipore                    Cat. \#: 05--636                                               WB (1:5000)
                                           anti-gH2AX                                                                                                                                  

  Antibody                                 Mouse\                                      Santa Cruz                       Cat. \#: sc-9996                                               IF (1:200), WB\
                                           anti-GFP                                                                                                                                    (1:5000)

  Antibody                                 Mouse anti-Cyclin\                          CalBiochem                       clone E23                                                      IF (1:100)
                                           A2                                                                                                                                          

  Antibody                                 Rabbit\                                     Abcam                            Cat. \#: ab21083                                               IF (1:200)
                                           anti-53BP1                                                                                                                                  

  Antibody                                 Mouse\                                      Santa Cruz                       Cat. \#: sc-166667                                             WB (1:1000)
                                           anti-POLK                                                                                                                                   

  Antibody                                 Mouse\                                      Santa Cruz                       Cat. \#: sc-17770                                              WB (1:1000)
                                           anti-POLH                                                                                                                                   

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A301-304A                                             WB (1:5000)
                                           anti-POLI                                                                                                                                   

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A300-094A                                             WB (1:5000)
                                           anti-MCM2                                                                                                                                   

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A300-195A                                             WB (1:5000)
                                           anti-MCM5                                                                                                                                   

  Antibody                                 Rabbit anti-\                               Abcam                            Cat. \#: ab1791                                                WB (1:5000)
                                           Histone H3                                                                                                                                  

  Antibody                                 Rabbit\                                     Abcam                            Cat. \#: ab180579                                              WB (1:5000)
                                           anti-REV7                                                                                                                                   

  Antibody                                 Rabbit anti-pRPA32 S33                      Bethyl                           Cat. \#: A300-246A                                             WB (1:5000)

  Antibody                                 Rabbit anti-pRPA32 S4/S8                    Bethyl                           Cat. \#: A700-009                                              WB (1:5000)

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A300-244A                                             WB (1:5000)
                                           anti-RPA32                                                                                                                                  

  Antibody                                 Mouse\                                      CalBiochem                       clone 2B                                                       WB (1:1000)
                                           anti-BRCA2                                                                                                                                  

  Antibody                                 Mouse\                                      BioLegend                        Cat. \#: 901502                                                WB (1:5000)
                                           anti-HA                                                                                                                                     

  Antibody                                 Goat\                                       Bethyl                           Cat. \#: A190-113A                                             WB (1:5000)
                                           anti-HisTag                                                                                                                                 

  Antibody                                 Rabbit\                                     Santa Cruz                       Cat. \#: sc-48806                                              WB (1:1000)
                                           anti-REV1                                                                                                                                   

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A301-254A                                             WB (1:5000)
                                           anti-FANCI                                                                                                                                  

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A300-193A                                             WB (1:5000)
                                           anti-MCM4                                                                                                                                   

  Antibody                                 Rabbit\                                     Bethyl                           Cat. \#: A300-192A                                             WB (1:5000)
                                           anti-MCM3                                                                                                                                   

  Antibody                                 Rabbit\                                     Abcam                            Cat. \#: ab63801                                               WB (1:5000)
                                           anti-Rad51                                                                                                                                  

  Antibody                                 Rabbit anti-pRPB1 CTD S2                    Cell Signaling                   Cat. \#: E1Z3G                                                 WB (1:1000)

  Antibody                                 Mouse\                                      Cell Signaling                   Cat. \#: 2629                                                  WB (1:1000)
                                           anti-RPB1 CTD                                                                                                                               

  Antibody                                 Rabbit\                                     Cell Signaling                   Cat. \#: C13C1                                                 WB (1:5000)
                                           anti-pCHK2 T68                                                                                                                              

  Recombinant DNA reagent                  Fugene 6 Transfection reagent               Promega                          E2692                                                          

  Recombinant DNA reagent                  Lipofectamine RNAiMAX                       Invitrogen                       Cat \#: 13778150                                               

  Sequence-\                               CRISPR guide\                               This Paper                                                                                      See Materials and methods
  based reagent                            RNAs (sgPolK\#1,\#2)                                                                                                                        

  Sequence-\                               siRNAs                                      This Paper                                                                                      See Materials and methods
  based reagent                                                                                                                                                                        

  Sequence-\                               Mutagenesis\                                This Paper                                                                                      See Materials and methods
  based reagent                            primers                                                                                                                                     

  Peptide,\                                Tri-Ubiquitin chains (K48-linked)           Boston Biochem                   UC-215B                                                        
  recombinant\                                                                                                                                                                         
  protein                                                                                                                                                                              

  Peptide,\                                Tri-Ubiquitin chains (K63-linked)           Boston Biochem                   UC-315B                                                        
  recombinant\                                                                                                                                                                         
  protein                                                                                                                                                                              

  Peptide,\                                USP2 Catalytic Domain (CD)                  Boston Biochem                   E-504                                                          
  recombinant\                                                                                                                                                                         
  protein                                                                                                                                                                              

  Peptide,\                                AMSH                                        Boston Biochem                   E-548B                                                         
  recombinant\                                                                                                                                                                         
  protein                                                                                                                                                                              

  Peptide,\                                SARS PLPro                                  Boston Biochem                   E-610                                                          
  recombinant\                                                                                                                                                                         
  protein                                                                                                                                                                              

  Commercial\                              Click-it EdU Imaging Kit                    Invitrogen                       C10339                                                         
  assay or kit                                                                                                                                                                         

  Commercial\                              Click-it EdU Flow Cytometry Assay Kit       Invitrogen                       C10646                                                         
  assay or kit                                                                                                                                                                         

  Commercial\                              QuikChange XL Mutagenesis Kit               Agilent                          Cat \#: 200517                                                 
  assay or kit                                                                                                                                                                         

  Commercial\                              TOPO-TA Cloning Kit for Sequencing          Invitrogen                       Cat \#: 450071                                                 
  assay or kit                                                                                                                                                                         

  Chemical\                                Hydroxyurea (HU)                            Sigma                            H8627                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Aphidicolin (APH)                           Sigma                            A4487                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Gemcitabine (Gem)                           Sigma                            G6423                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Mirin                                       Sigma                            M9948                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                AZD7762 (CHK1 inhibitor)                    Sigma                            SML0350                                                        
  compound, drug                                                                                                                                                                       

  Chemical\                                1-b-D-ribofuranoside (DRB)                  Sigma                            D1916                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Flavopiridol (FVP)                          Sigma                            F3055                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Formaldehyde 37% w/v                        VWR                              M134                                                           
  compound, drug                                                                                                                                                                       

  Chemical\                                Glycine                                     Fischer Scientific               BP381                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                5\'-Iodo-2\'-deoxyuridine (IdU)             Sigma                            I7125                                                          
  compound, drug                                                                                                                                                                       

  Chemical compound, drug                  5\'-chloro-2\'-deoxyuridine (CldU)          Sigma                            C6891                                                          

  Chemical\                                5\'-ethynyl-2-deoxyuridine (EdU)            Sigma                            Cat \#: 900584                                                 
  compound, drug                                                                                                                                                                       

  Chemical\                                Thymidine (dT)                              Sigma                            T1895                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                2\'-deoxycytidine\                          Sigma                            D0776                                                          
  compound, drug                           HCl (dC)                                                                                                                                    

  Chemical\                                2\'-deoxyadenosine\                         Sigma                            D8668                                                          
  compound, drug                           (dA)                                                                                                                                        

  Chemical\                                2\'-deoxyguanosine\                         Sigma                            D0901                                                          
  compound, drug                           (dG)                                                                                                                                        

  Chemical\                                Cytidine (rC)                               Sigma                            C4654                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Adenosine (rA)                              Sigma                            A4036                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Guanosine (rG)                              Sigma                            G6264                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Uridine (rU)                                Sigma                            U3003                                                          
  compound, drug                                                                                                                                                                       

  Chemical\                                Anti-GFP mAb agarose beads                  MBL                              Cat \#: D153-8                                                 
  compound, drug                                                                                                                                                                       

  Chemical\                                Dynabeads Myone Streptavidin T1             ThermoFisher Scientific          Cat \#: 65601                                                  
  compound, drug                                                                                                                                                                       

  Chemical\                                Biotin Azide                                ThermoFisher Scientific          Cat \#: B10184                                                 
  compound, drug                                                                                                                                                                       

  Chemical\                                Protein G beads agarose                     ThermoFisher\                    Cat \#: 20399                                                  
  compound, drug                                                                       Scientific                                                                                      

  Chemical\                                SYPRO Ruby Protein Gel Stain                ThermoFisher Scientific          Cat \#: S12000                                                 
  compound, drug                                                                                                                                                                       

  Chemical\                                cOmplete Mini Protease Inhibitor Cocktail   Sigma                            Cat \#: 11836170001 (Roche)                                    
  compound, drug                                                                                                                                                                       

  Software,\                               GraphPad Prism                              (<https://graphpad.com>)         RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)   
  algorithm                                                                                                                                                                            

  Software,\                               ImageJ                                      (<https://imagej.nih.gov/ij/>)   RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)   
  algorithm                                                                                                                                                                            

  Software,\                               FlowJo                                      (<https://www.flowjo.com/>)      RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)   
  algorithm                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s4-1}
------------

U2OS and 293 T cells (ATCC) were grown at 37°C in DMEM (Gibco) with 10% FBS (Atlantic Biologicals), 1% penicillin/streptomycin (Gibco), and 1% glutamine (Gibco). hTERT-immortalized RPE-1 cells (ATCC) were grown in DMEM/F12 (Gibco) with 10% FBS, 1% penicillin/streptomycin,. 25% Sodium Bicarbonate (Gibco). PD20 patient cells ([@bib17]; [@bib58]) were grown in DMEM with 15% FBS, 1% penicillin/streptomycin and 1% glutamine. All cell lines were tested for mycoplasma using the Roche MycoTOOL detection kit. All cell lines, except for the PD20 cells, were also authenticated by short tandem repeat (STR) profiling.

DNA fiber analysis {#s4-2}
------------------

DNA fibers were prepared as described previously ([@bib13]). Briefly, cells were pulsed with 50 μM IdU and CldU for times indicated in each experiment. After trypsinization, cells were washed and resuspended at 1 × 10\^6/mL in cold PBS, 2 uL were plated onto a glass slide, and lysed with 10 uL lysis buffer (0.5% SDS, 200 mM Tris-HCl pH 7.4, 50 mM EDTA) for 6 min. Slides were tilted at a 15 degree angle to allow DNA spreading, and then fixed for 3 min in chilled 3:1 methanol:acetic acid. The DNA was denatured with 2.5 N HCl for 30 min, washed in PBS, blocked for 1 hr in 5% BSA in PBS with 0.1% Triton X-100. Slides were stained for 1 hr with primary antibodies, washed 3X in PBS, stained for 30 min with secondary antibodies, washed 3X in PBS and dried. Coverslips were mounted with Prolong antifade reagent and sealed. Slides were imaged with Keyence BZ-X710 microscope. Image analysis was done with ImageJ. A minimum of 150 fibers were measured for each independent experiment for percentage of restart, and analysis shows mean of three independent experiments. A minimum of 60 fiber lengths were measured for each independent experiment measuring tract length, and analysis shows the pool of three independent experiments (biological replicates). Tract lengths were calculated by converting μm measured in ImageJ to kb using the conversion 1 μm = 2.59 kb ([@bib44]).

Western blotting {#s4-3}
----------------

Western blots were performed with whole-cell extracts prepared in SDS sample buffer (0.1M Tris pH 6.8, 2% (w/v) SDS and 12% (v/v) β-mercaptoethanol). Protein extracts were separated on Nupage 4--12% Bis-Tris or 3--8% Tris-Acetate gels (Invitrogen). Proteins were transferred onto 0.45 μM PVDF membrane in Invitrogen Tris-Glycine transfer buffer. Membranes were blocked in 5% milk in TBST for 1 hr and incubated in primary antibody overnight. Next day membranes were incubated with secondary antibodies in 5% milk TBST for 2 hr at room temperature and developed using Western Lightning Plus-ECL reagent. For detection of BRCA2 protein, cells were lysed directly on the plate with ice-cold NP-40 lysis buffer (50 mM HEPES pH 7.5, 250 mM NaCl, 1% NP-40, 0.5 mM EDTA, 1 mM DTT, supplemented with Roche protease inhibitor cocktail) for 10 min on ice, scraped and transferred into an Eppendorf tube, and spun at 4°C for 10 min at 14 k rpm. Lysates were heated to 54°C for 4 min prior to loading onto a 3--8% Tris-Acetate gel, and all subsequent steps were performed as described above.

Cross-linking Immunoprecipitation {#s4-4}
---------------------------------

Crosslinking protocol was performed as described in [@bib27], but with slight modifications. Briefly, one 10 cm plate of cells per sample was washed once in PBS, cross-linked for 10 min with 3 mL 1% formaldehyde in PBS, and terminated with 300 μL of 1.25M glycine. Cells were then scraped and transferred into a falcon tube, washed 3X in cold PBS, and resuspended in 250 μL lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.3% SDS) and lysed for 10 min at RT. Samples were sonicated using microtip sonicator as follows: 3 pulses at 33% amplitude for 12 s with 30 s on ice in between, and one final pulse at 40% amp for 12 s. Lysates were centrifuged at high speed for 5 min, transferred to a new tube, and diluted 1:8 in dilution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% Triton). Samples were then incubated at 4°C overnight with antibody. The following day, samples were incubated for 1 hr at 4°C with 20 μL of 50% slurry Protein G beads. Beads were then washed 4X in 500 μL dilution buffer, and boiled for 15 min in 4X Lamelli buffer supplemented 100 mM DTT. GFP-IPs were performed using GFP-agarose beads incubated overnight in place of antibody, with the subsequent 4X washes performed the next day.

iPOND {#s4-5}
-----

iPOND experiments were performed as described in [@bib16]. In brief, three 15 cm plates of 293 T cells were prepared per sample, and treated for 10 min with 10 μM EdU, or pretreated for 1 hr with 2 mM HU incubation followed by 4 hr with 2 mM HU and 10 μM EdU. Chases were performed for 1 hr with 10 μM thymidine. Plates were cross-linked with 10 mL 1% formaldehyde in PBS for 20 min and terminated with 1 mL 1.25M glycine. Cells were scraped and transferred into a 50 mL falcon tube, washed 3X in PBS. Cells were resuspended in 0.25% Triton for 30 min at RT, and washed once in 0.5% BSA in PBS and once in PBS. Cells were resuspended in click reaction (2 mM CuSO4, 10 mM sodium ascorbate, and 10 μM biotin azide in PBS) for 2 hr at RT and then washed once in 0.5% BSA in PBS and once in PBS. Cell pellets were resuspended in 1 mL lysis buffer (50 mM Tris pH 8, 1% SDS with protease inhibitor (Roche)), and sonicated for 20 s at 40% amplitude with 1 min on ice for a total of 5 pulses. After centrifugation, lysates were transferred to a new tube and diluted 1:1 in PBS. Next, 25 μL of streptavidin magnetic beads (Thermo Fisher) (washed 3X in PBS) were added and incubated overnight at 4°C. Beads were washed in 1 mL of cold lysis buffer, 1 mL of 1M NaCl, and then two more washes with cold lysis buffer. Proteins were eluted with addition of 2X SDS loading buffer (5% SDS, 25% glycerol, 0.15M Tris pH 6.8, 200 mM DTT) and boiled at 95°C for 25 min. Samples were then loaded into NuPage gels and western was performed as described.

Ubiquitin chain restriction and ubiquitin cleavage assays {#s4-6}
---------------------------------------------------------

Protocol for ubiquitin chain cleavage assays was performed as described previously ([@bib5]). In vitro reactions were performed in 150 mM NaCl, 20 mM Tris pH 8 using 0.5 μg ubiquitin chains (Boston Biochem). Reactions with SARS PLpro or USP2 Catalytic Domain (CD) also contained 5 mM DTT. Samples were incubated with 100 ng of each DUB at 37°C for the times indicated. Reactions were terminated by addition of 4X Lamelli buffer and boiling for 10 min. Samples were loaded onto NuPage 4--12% Bis Tris gels, stained using SYPRO Ruby gel stain (BioRad), and imaged on BioRad EZ Gel Doc detector. For cross-linked IP samples, beads were washed 3X in dilution buffer, and then buffer exchanged with 4 × 500 μL washes in reaction buffer above. Reactions were then performed for 1 hr at 37°C with 900 ng of enzyme and terminated similarly.

Immunofluorescence {#s4-7}
------------------

EdU imaging was performed according to Click-It EdU Imaging Kit protocol (Invitrogen) with slight modifications. Cells were grown on coverslips and fixed in 3.7% formaldehyde for 15 min at RT, and washed with 3% BSA in PBS. Coverslips were permeabilized in 0.5% Triton X-100 for 20 min at RT and washed twice in 3% BSA. Coverslips were incubated in click reaction buffer for 30 min at RT and washed once in 3% BSA. For subsequent antibody incubations, coverslips were blocked for 1 hr in 2%BSA, 0.2% Triton at RT, and incubated for 2 hr at RT with primary antibody. Coverslips were washed 2X in blocking buffer, incubated for 45 min secondary antibody, washed 2X in blocking buffer and then once in PBS. Coverslips were mounted onto glass slides using Vectashield with DAPI. For regular immunofluorescence, cover slips were fixed for 10 min in 3.7% formaldehyde (most antibodies), or 10 min in 3.7% formaldehyde followed by a 5 min ice-cold methanol fixation (Cyclin A staining). Cover slips were permeabilized for 10 min with 0.5% Triton-X 100, and blocking and staining was performed similarly as described.

Single-molecule localization microscope {#s4-8}
---------------------------------------

The Single-molecule localization imaging was performed on a customized inverted microscope as described previously ([@bib13]). In brief, the 640 nm (UltraLaser, MRL-FN-639--800), 561 nm (UltraLaser, MGL-FN-561--200), and 488 nm (OBIS) laser lines were collimated and reflected by a penta-edged dichroic beam splitter (FF408/504/581/667/762-Di01) into an TIRF Objective (HCX PL APO 63X NA = 1.47, Zeiss). The illuminations were adjusted into a HILO mode and tuned to \~0.8, 1.0, and 1.5 kW/cm^2^, respectively, for nucleus imaging. The emitted fluorescence was further magnified by a 2X lens tube (Diagnostic Instruments) before collected onto am sCMOS camera (Prime 95B, Photometrics). After the 2X magnification, the emitted fluorescence was filtered by a single-band filter (Semrock FF01-676/37 for Alexa Fluor 647 for EdU detection in [Figure 5](#fig5){ref-type="fig"}, and FF01-809/81 and FF01-607/36 for Alexa Fluor 488 and 568, respectively, for GFP-PolK and PCNA detection in [Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}, in which the multiplexed imaging was accomplished by sequentially switching the illumination laser and such filters accordingly). The photons were then recorded at 33 Hz for 2000 frames for each imaging. Each image taken from different color channels ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}) were mapped using a 2nd polynomial mapping algorithm. In brief, before each imaging, the broad-spectrum fluorescent beads (TetraSpec, Thermo Fisher) were imaged in different color-channels, and the mass centers recorded in each channel were submitted for 2nd polynomial regression, which then optimized the 2nd polynomial's ecoefficiency for mapping the nucleus images.

Single-molecule localization {#s4-9}
----------------------------

After collecting 200 frames for each imaging, the single-molecule image stack was submitted to a home-built software for precise single-molecule localization. In brief, each frame from an image stack was box filtered, roughly-local-maxima-localized, segmented, and submitted to GPU for parallel fitting each single Point-Spread-Function (PSF) using the Maximum Likelihood Estimation (MLE), and the fitting accuracy was evaluated using Cramer-Rao Lower Bound (CRLB) estimation. We note that the patterned read-out noise of the sCMOS camera was calibrated before imaging. Such read-out noise for each pixel was approximated into a Gaussian distribution and contributed to the MLE fitting for each single PSF ([@bib46]). The coordinates were then submitted for Auto-Pair-Correlation ([Figure 5d and e](#fig5){ref-type="fig"}) [Figure 5D, E](#fig5){ref-type="fig"} and Cross-Pair-Correlation ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}). The Pair-Correlation function uses the molecular coordinates obtained from the single-molecule localization experiments to define the average probability density of finding fluorophores with specific molecular proximities around each fluorophore. By integrating the probability density profile of each cell and multiplying with the average density of fluorophores detected in the nucleus, we can derive the average number of fluorophores within a cluster ([@bib51]). Since EdU was \~1:1 tagged by fluorophores via click chemistry, such number of fluorophores per cluster is proportional to the number of EdU molecules per focus. Using these algorithms, we can arrive at the number of EdU molecules per focus and estimate the number of EdU foci per nucleus by dividing the relative total number of EdU in each nucleus by the average number of EdU per focus. The statistics of [Figure 5D](#fig5){ref-type="fig"} is mean ± s.d., N = 59, 43, 38, and 55 nuclei for siCtrl, siPolK, siFANCD2, and siFANCD2 +siPolK, respectively. For [Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}, the mean ±s.d., N = 15, 21, 18, and 18 nuclei for WT_NT, CD_NT, WT_HU, and CD_HU, respectively.

Flow cytometry {#s4-10}
--------------

Protocol was performed according to Click-It EdU Flow Cytometry Imaging Kit (Invitrogen). Cells were labeled with 10 μM EdU for 1 hr prior to HU treatment and subsequent chases. Cells were fixed for 15 min in 3.7% formaldehyde, washed in 3% BSA, and resuspended in Saponin buffer. Cells were incubated with click reaction buffer for 30 min at RT and washed once in saponin based wash reagent. Pellets were resuspended in 200 μL and incubated with primary antibody for 2 hr. Pellets were washed twice in 3 mL saponin wash buffer, and incubated for 1 hr with secondary antibody and washed once. Pellets were then resuspended in 500 μL of saponin buffer containing 1 mg/mL DAPI with RNase A and incubated for 1 hr at 37°C. Cells were analyzed with LSRII UV flow cytometer and analysis done using FlowJo software.

Senescence-associated β galactosidase staining {#s4-11}
----------------------------------------------

Protocol was performed as described ([@bib30]). Briefly, cells were plated in 12-well or 6-well plates. Following 4 hr HU treatment and chase, cells were fixed with 2% formaldehyde, 0.2% glutaraldehyde for 10 min, washed in PBS, and incubated overnight in humidified 37°C chamber in SA-βGal staining solution (25.2 mM sodium phosphate dibasic, 7.34 mM citric acid at pH 6, 150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mg/mL X-gal). Following morning cells were washed 3X in water, stained with DAPI, and imaged with bright-field microscopy.

Plasmids, primers, siRNAs, and CRISPR sgRNAs {#s4-12}
--------------------------------------------

Transient plasmid transfections were performed using FuGene six reagent (Promega), and siRNA transfections were performed using Lipofectamine RNAiMax (Invitrogen), both according to manufacturer's instructions. Analyses were done between 24--48 hr after plasmid transfection and 72 hr after siRNA transfection. CRISPR generation was performed using the pX330 system from the Feng Zhang lab with puromycin resistance cloned by the Agnel Sfeir lab (gift). Sanger sequencing of CRISPR clones was performed on gDNA fragments cloned into TOPO TA vector (Thermo Fisher). Site directed mutagenesis was performed using Agilent xL kit according to manufacturer's instructions. TLS constructs are in eGFP-C1 vectors (Clontech). PolK CD (catalytic dead mutant)=D198A/E199A, PolK UBZ (double UBZ mutant)=D644A/D799A. The siRNA-resistant HA-PCNA WT and K164R constructs were cloned in pcDNA3.1 vector, and was generated previously ([@bib25]). siRNA target sequences (Qiagen) used in this study:

*PolK* siRNA (siPolK): \#1, 5'-TGGAATTAGAACAAAGCCGAA-3',

\#2, 5'-AACCTCTAGAAATGTCTCATA-3'

*PolH* siRNA (siPolH): \#1, 5'-ATCCATTTAGGTGCTGAGTTA-3', \#2, 5'-CAGCCAAATGCCCATTCGCAA-3'

*PolI* siRNA (siPolI): \#1, 5'-GCGGTTTATTAAGCTCTTCTA-3', \#2, 5'-TTCGGATTAGCGGTTTATTAA-3'

*Rev1* siRNA (siRev1): \#1, 5'-CAGCGCATCTGTGCCAAAGAA-3', \#2, 5'-

CTGCCAGGTCCAAGCAATATA-3'

*MAD2L2* siRNA (siRev7): \#1, 5'-GTGGAAGAGCGCGCTCATAAA-3', \#2, 5'-AAGATGCAGCTTTACGTGGAA-3'

*REV3L* siRNA (siRev3L): \#1, 5'- CGGGATGTAGTCAAACTGCAA-3', \#2, 5'- ATGAGTATGGATCATATACAA-3'

*PCNA* siRNA (siPCNAresist): 5'- GCCGAGATCTCAGCCATATTT-3'

*TP53* siRNA (siP53): 5' CAGAGTGCATTGTGAGGGTTA-3'

*FANCD2* siRNA (siFANCD2): 5'- AACAGCCATGGATACACTTGA-3'

*RAD51* siRNA (siRad51): \#1, 5'- CAGGATAAAGCTTCCGGGAAA-3', \#2, 5'- CACTTCTAAATTAATGGTAAA-3'

*BRCA2* siRNA (siBRCA2): \#1, 5'- CAGCGTTTGTGTATCGGGCAA-3', \#2, 5'- TACGTACTCCAGAACATTTAA-3'

*SMARCAL1* siRNA (siSMARCAL1): 5'-TTGAGTTATGAGTTAGGTCAA--3' sgPolK guides: \#1, 5' GAAGACTCATGGCCATAAAAT-3', \#2, 5'- GATTGGCCTGAGGATAAAAGA-3'

Primers for site-directed mutagenesis:

PolK CD: fwd: 5'-CAATTTTATGGCCATGAGTCTTGCTGCAGCCTACTTGAATATAACAAAGC-3'

PolK UBZ1: fwd, 5'- CCTTGAATAAACATGTAGCCGAATGTCTTGATGGACC-3'

PolK UBZ2: fwd, 5'-CTGTTCAATGTGCATGTGGCCGTTTGCTTAAATAAAAG-3'
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Decision letter

Nussenzweig

Andre

Reviewing Editor

Center for Cancer Research, National Cancer Institute, NIH

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Translesion polymerase kappa-dependent DNA synthesis underlies replication fork recovery\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jessica Tyler as the Senior Editor. The following individual involved in review of your submission has agreed to reveal her identity: Kristin Eckert (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors demonstrate the role of translesion (TLS) polymerases in protecting and restarting stalled replication fork specifically under nucleotide deprived condition (i.e. hydroxyurea-induced stalling). Based on their initial screen of various TLS polymerases by employing the single-molecule DNA fiber technique coupled with siRNA strategy, the authors singled out PolK as the key polymerase responsible in promoting fork restart. This approach also revealed that PolK is epistatic to the Fanconi Anemia (FA) pathway in facilitating fork restart. In addition, through complementation approach, the authors demonstrated that both catalytic and PCNA-interacting domain of PolK is responsible in mediating fork restart; interestingly, only the PCNA-interacting domain is critically involved in preventing nascent DNA degradation. Collectively, this is a very interesting and well-conducted study that points to a previously unappreciated role of PolK in genome stability and replication stress recovery. However, several concerns need to be addressed, as indicated below.

Essential revisions:

1\) One of the most salient issues brought up by two reviewers pertains to the major conclusion that nucleotide deprivation (through addition of HU) is the underlying cause of the reliance on PolK in fork restart and protection. Alternative pathways may contribute to replication stress by HU (for instance, transcriptional R loops cause replication stress, and DNA breaks in HU treated cells preferentially occur at genes transcriptionally induced by HU (Hoffman et al., 2015)). Moreover, HU is not a specific inhibitor of ribonucleotide reductase, and has been shown to induce oxidative stress in cells by affecting other Fe-S cluster enzymes (Huang et al., 2016). The reviewers are requesting the authors to provide additional experimental evidence that the phenotypes are due to nucleotide deprivation; by either:

a\) Adding exogenous nucleosides to the culture media and measure whether the key molecular phenotypes are reversed (see Técher et al., 2016; Aird et al., 2013).

b\) Utilizing a different stalling condition on some of the key data, for example aphidicholin which inhibits the DNA replication machinery without affecting the nucleotide pool level.

2\) When discussing the results of Figure 4A, the authors state that \"PolK depletion further reduced DNA synthesis (or fork speed) during HU treatment, as measured by reduced CldU tract length adjacent to IdU tracts\". Could this reduction be due to the fact that PolK depleted cells have a defect in fork restart? During the time of HU treatment, replication forks will continuously stall and restart, and the reduced efficiency of restart associated with the loss of PolK could lead to shorter CldU tracts.

3\) Figure 5. The authors should test how the cell cycle detects and the 53BP1 nuclear body formation accumulation observed upon PolK loss are affected by co-depletion of FANCD2 and PolK to confirm that these proteins act within the same pathway.

4\) The authors show (Figure 2) that Pol kappa-deficiency does not affect Chk1 signaling in response to high dose HU treatment. This result directly contradicts a previous study (Bétous et al., 2013) and impacts ongoing discussions regarding reproducibility in science. This discrepancy is important for the field to reconcile. The authors should provide more information regarding possible differences in cell lines (genetic differences), doses, antibodies used, or other possible experimental reasons underlying differences.

5\) Why does the expression of PolK UBZ mutant in the complementation experiment decrease the CldU track length as compared to vector (Figure 3B)? Is this statistically significant, and if so, what this may indicate mechanistically? It would be wise to add this in the Discussion section.

6\) Figure 4D. Why FANCD2 depletion does not affect EdU foci counts while it increases the CldU tract lengths in Figure 4A?
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Author response

> Essential revisions:
>
> 1\) One of the most salient issues brought up by two reviewers pertains to the major conclusion that nucleotide deprivation (through addition of HU) is the underlying cause of the reliance on PolK in fork restart and protection. Alternative pathways may contribute to replication stress by HU (for instance, transcriptional R loops cause replication stress, and DNA breaks in HU treated cells preferentially occur at genes transcriptionally induced by HU (Hoffman et al., 2015)). Moreover, HU is not a specific inhibitor of ribonucleotide reductase, and has been shown to induce oxidative stress in cells by affecting other Fe-S cluster enzymes (Huang et al., 2016). The reviewers are requesting the authors to provide additional experimental evidence that the phenotypes are due to nucleotide deprivation; by either:
>
> a\) Adding exogenous nucleosides to the culture media and measure whether the key molecular phenotypes are reversed (see Técher et al., 2016; Aird et al., 2013).
>
> b\) Utilizing a different stalling condition on some of the key data, for example aphidicholin which inhibits the DNA replication machinery without affecting the nucleotide pool level.

To address the concern of HU potentially having indirect (off target) effects, such as increased ROS that may affect the interpretation of our results, we have now modified the restart assay by supplementing deoxynucleosides in addition to CldU to the high dose HU (2mM) medium (under continuous HU treatment), in comparison to our standard restart assay where the HU is washed away and replaced with fresh media and CldU. Doing so resulted in nearly identical levels of stalled forks between the two different control samples and also for the Pol kappa-depleted samples (new Figure 1C). This demonstrates that HU-induced nucleotide deprivation is likely the major cause of stalled forks in the fork restart assay. In addition, we now show via Western blot that only by adding deoxynucleosides, but not ribonucleosides, can we down-regulate checkpoint signaling (as measured by phospho-Chk1 and phospho-RPA32) in the presence of HU to levels similar to washing off HU during the recovery step (new Figure 1D). We think this is a very nice control showing that only deoxynucleoside supplementation (not ribonucleoside) will enable recovery from checkpoint activation and elevated stalled forks in HU-treated cells. This isn't surprising since HU is known to potently inhibit ribonucleotide reductase (RNR) to prevent the generation of deoxyribonucleotides from ribonucleotides. Adding excess ribonucleosides to the media would not circumvent this problem when RNR is already inhibited by HU.

To address the potential universal stalled fork role of Pol kappa in fork rescue, we tested whether Pol kappa is involved in fork restart using different stalling conditions, such as aphidicolin, which inhibits the DNA replication machinery without affecting the nucleotide pool level. We provide new data showing that Pol kappa does not play a role in replication restart after aphidicolin treatment (new Figure 1E). Interestingly, we found that the levels of stalled forks are higher in control samples after aphidicolin treatment compared to high dose HU (new Figure 1E), implying that recovering from stalling by direct replicative DNA polymerase inhibition is a distinct mechanism from disruption of nucleotide pool levels. We also attempted to use gemcitabine as a drug that can also inhibit ribonucleotide reductase but with a mechanism distinct from HU, and has been used as a fork stalling agent (Mini et al., 2003, Annals of Oncology; Schlacher et al., 2012). Performing the DNA fiber assay with 1μM gemcitabine yielded no CldU tracts following drug wash off (new Figure 1---figure supplement 2A), implying an inability for forks to restart, which is likely due to the difficulty of reversing the effects of gemcitabine treatment, especially when it acts as a nucleoside poison. In support of this finding, we show that washing off gemcitabine is unable to reduce phospho-Chk1 or phospho-RPA32 signaling compared with HU or aphidicolin, even when used at doses as low as 100nM (new Figure 1F and Figure 1---figure supplement 2B). This is likely due to gemcitabine's other roles as a DNA polymerase inhibitor and chain terminator.

To address if any effects can be attributed to replication-transcription conflicts that may occur during the high-dose HU treatments, we utilized inhibitors of RNA Pol II transcription elongation (DRB and flavopiridol) in coordination with 2mM HU. Based on Cimprich and colleagues' recent work and others (Hamperl et al., 2017, Cell; Sanz et al., 2016, Mol Cell), transcriptional R loops that lead to DNA breaks occur at transcribed genes, which could be mitigated by blocking RNA Pol II transcription elongation. As shown by western, treatment with DRB or flavopiridol (FVP), two inhibitors of CDK9, does not affect checkpoint signaling in response to HU treatment (new Figure 4---figure supplement 1B). In addition, treatment with DRB shows no change in the length of CldU incorporation under HU in both control and Pol kappa-depleted samples (new Figure 4---figure supplement 1A), showing that the slow DNA synthesis and travel of the fork under high-dose HU is not affected by replication-transcription conflicts that can be mitigated, in part, by DRB treatment.

> 2\) When discussing the results of Figure 4A, the authors state that \"PolK depletion further reduced DNA synthesis (or fork speed) during HU treatment, as measured by reduced CldU tract length adjacent to IdU tracts\". Could this reduction be due to the fact that PolK depleted cells have a defect in fork restart? During the time of HU treatment, replication forks will continuously stall and restart, and the reduced efficiency of restart associated with the loss of PolK could lead to shorter CldU tracts.

This is an interesting point made by the reviewers, but if this hypothesis were correct, then one would also expect that depletion of FANCD2, which has a defect in fork restart, to also show reduced CldU tracts adjacent to IdU tracts. Depletion of FANCD2, however, increases the CldU synthesis under high-dose HU, seen in this report and others (Chen et al., 2015; Lossaint et al., 2013). It is hard to imagine that DNA synthesis during HU would be discontinuous at the leading strand with fits of stops and restarts, but we can't formally rule out this possibility without further in vitro analysis, which we think is beyond the scope of this study. We have modified our discussion of the Figure 4A results according to the suggestion of the reviewers (subsection "PolK protects forks against SMARCAL1- and MRE11-dependent nascent DNA degradation").

> 3\) Figure 5. The authors should test how the cell cycle detects and the 53BP1 nuclear body formation accumulation observed upon PolK loss are affected by co-depletion of FANCD2 and PolK to confirm that these proteins act within the same pathway.

This is a critical point brought up by the reviewers. We now provide new evidence to show that co-depletion of Pol kappa and FANCD2 leads to similar levels of 53BP1 nuclear bodies as well as senescence-associated b-galactosidase staining (new Figure 6C and Figure 6---figure supplement 1B), indicating that these two proteins are acting in the same pathway after transient nucleotide deprivation to prevent genomic instability and cell cycle defects.

> 4\) The authors show (Figure 2) that Pol kappa-deficiency does not affect Chk1 signaling in response to high dose HU treatment. This result directly contradicts a previous study (Bétous et al., 2013) and impacts ongoing discussions regarding reproducibility in science. This discrepancy is important for the field to reconcile. The authors should provide more information regarding possible differences in cell lines (genetic differences), doses, antibodies used, or other possible experimental reasons underlying differences.

We appreciate the concerns of the reviewers regarding reproducibility in science, but we have a fundamental disagreement with this policy. It shouldn't be up to us to go out of our way to try to prove or disprove other fellow scientists in the field. The only thing we can control is our own set of results and data analysis. We can only speculate why there may be discrepancies in science, some could involve more tabloid-like discussions. But in this case, the best thing to do is to take the long view of research and science. In general, time is the greatest arbiter of science. If there haven't been any follow-up studies regarding the role of Pol kappa and Chk1 signaling (and there hasn't been since 2013), then most likely the effect is either too modest to be followed up by other researchers in the crowded DNA damage response field, or the effect is too difficult to capture reproducibly. Logically, if the loss of Pol kappa truly had a checkpoint defect, the Pol kappa-deficient mice would have a more severe phenotype, bordering an ATM or ATR-like hypomorphic condition. The Pol kappa KO mice have relatively mild phenotype (no developmental defects or cancer predisposition). That being said, we are currently using Pol kappa KO mice to interrogate endogenous replication stress inducers, looking at cell type-specific effects in a more endogenous setting. We hope to report this phenotype soon, but this is currently beyond the scope of our study in this manuscript.

In regards to the Bétous et al. (2013) study, there are similarities in the cell lines used and dosages of HU performed between our current study and theirs. Both show U2OS and 293T cells, and both use 2mM HU for similar time points (3 hrs in Bétous et al., versus 4 hours in our manuscript). However, there are some issues in interpreting some figures. For instance, in their manuscript regarding Figure 1C, Figure 5B, Supplementary Figure 1D, and Supplementary Figure 1F, they all show reduced total Chk1 protein levels, which could explain the decrease in the phospho-Chk1 they observed. In their Figure 1E, they attempt to show that reduced Pol kappa activity leads to reduction in phospho-Chk1 levels by expressing a catalytic dead Pol kappa in MRC5 cells. In their figure there were no untreated control to compare phospho-Chk1 levels, and the levels of kappa expression were not shown. In contrast, we have evidence that overexpression of a catalytic dead (CD) version of Pol kappa actually leads to increased phospho-Chk1 levels in untreated cells, but shows no changes of checkpoint signaling upon 2mM HU treatment (see [Author response image 1](#respfig1){ref-type="fig"}). Our interpretation here is that prolonged Pol kappa usage in unperturbed cells (due to USP1 knockdown or p21 knockdown, which prevents the recycling of Pol kappa) is a bad thing, as this would lead to more fork stalling and slower replication forks, under-replicated DNA, and genomic instability (see Jones et al., 2012; Mansilla et al., 2016). Therefore, expression of a Pol kappa catalytic mutant would further exacerbate this problem, resulting in recruitment of a dead DNA polymerase to a replication fork, leading to increased fork stalling and elevated levels of checkpoint signaling. However, we feel that the effect of expressing the Pol kappa catalytic mutant in unperturbed cells is not relevant in our current study since we are primarily studying how HU-induced stalled forks are rescued by Pol kappa; therefore, we decided to leave it out of the current manuscript.

![Showing expression of WT vs Catalytic-dead (CD) Pol kappa in Pol kappa sgRNA KO cells.\
Even in the absence of HU (2mM), the CD mutant has elevated Chk1 and RPA32 phosphorylation. This is in contrast to the Bétous et al. (2013) study showing that Pol kappa is required for Chk1 activation upon HU treatment.](elife-41426-resp-fig1){#respfig1}

> 5\) Why does the expression of PolK UBZ mutant in the complementation experiment decrease the CldU track length as compared to vector (Figure 3B)? Is this statistically significant, and if so, what this may indicate mechanistically? It would be wise to add this in the Discussion section.

After re-inspecting the results for Figure 3B, we recognized an error that images from one of the slides used from the UBZ dataset were acquired at a higher resolution from the microscope, however the scale conversion to μM used was that of the standard resolution similar to the rest of the data. This has been corrected and the data updated (new Figure 4B). We sincerely apologize for this oversight. Upon the re-analysis of this data, the average track length of CldU for the Pol kappa UBZ-expressed cells is only marginally shorter than the vector control (compare avg of 10.92 kb for vector control to 9.75 kb of the UBZ mutant) with a p value of 0.03. It is possible that expression of the UBZ mutant is acting as a mild dominant negative and binding to a protein required for the protection of stalled forks. One possibility is that since the UBZ mutant still retains minimal PCNA binding activity through its PIP box, it's possible that binding to PCNA, independent of its ubiquitin-binding capacity, could alter the PCNA dynamics at stalled forks, which somehow leads to increased nascent DNA degradation. We have modified the text to speculate on this point.

> 6\) Figure 4D. Why FANCD2 depletion does not affect EdU foci counts while it increases the CldU tract lengths in Figure 4A?

Unfortunately, we don't have a good explanation for this (we provide more discussion on the interpretation of our data in the subsection "PolK-mediated DNA synthesis during conditions of nucleotide starvation"). A prediction would be that with FANCD2 depletion, we would see an increase in the amount of EdU counts per foci, as there are longer CldU tracts as measured with DNA fiber analysis under HU treatment (compare Figure 5A and 5D). It is not clear why we do not observe this. We would have predicted, as pointed out by the reviewers, that the amount of EdU foci counts per nuclei correlates with the number of ongoing replication fork events in the nucleus, whereas the amount of EdU counts (molecules) per foci would correlate with the amount of EdU incorporation (DNA synthesis) at specific clusters of replication forks per event. This implies that single-molecule fork events quantified by nucleotide analog signal measurements using DNA fibers versus EdU signals via super-resolution is not based on a one- to-one direct correlation of a single elongating fork, but likely a cluster of fork events within an EdU focus as defined by super resolution. It is possible that the increased synthesis at each replication fork is 'diluted' by what is occurring at multiple forks in the nucleus, and so within each individual EdU focus the increase is not as significantly different. FANCD2 appears to be playing a role in supporting the number of forks undergoing active DNA synthesis as co-depletion of Pol kappa and FANCD2 reverses the number of EdU foci counts per nuclei, but maintains similar amounts of EdU counts per foci as with Pol kappa depletion alone. While Pol kappa and FANCD2 are epistatic for fork restart, other roles of FANCD2 cannot be ruled out, as it is known to interact with other HDR factors for DNA repair, and its role in inhibiting replication origin firing (Chen et al., 2015) also cannot be ruled out.
